Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / pleiotrophin



This biomarker is also known as:
  • NEGF1,
  • Osteoblast-specific factor 1,
  • heparin affin regulatory protein,
  • HBGF-8,
  • HARP,
  • Heparin-binding growth factor 8,
  • osteoblast-specific factor 1,
  • heparin-binding neurite outgrowth-promoting factor 1,
  • heparin binding growth factor 8,
  • Heparin-binding brain mitogen,
  • HBNF-1,
  • HBNF1,
  • heparin-binding growth factor 8,
  • OSF-1,
  • PTN,
  • HBBM,
  • Heparin-binding growth-associated molecule,
  • pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1),
  • HB-GAM,
  • Heparin-binding neurite outgrowth-promoting factor 1,
  • HBNF,
  • heparin-binding growth-associated molecule,
  • HBGF8,
  • heparin-binding brain mitogen,
  • neurite growth-promoting factor 1,

View in BioMuta


Pleiotrophin, or PTN, is a secreted growth factor found in osteoblasts and brain tissue. PTN induces neurite outgrowth and is mitogenic for fibroblasts, epithelial, and endothelial cells. It binds anaplastic lymphoma kinase (ALK) which induces MAPK pathway activation, an important step in the anti-apoptotic signaling of PTN and regulation of cell proliferation.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


Pleiotrophin has been identified in serum and lung cancer tissue or cell culture as a candidate lung cancer biomarker. Pleiotrophin was also observed up-regulated in lung cancer in this study. Others studies have suggested that pleiotrophin may be an early indicator of lung cancer and might be of use in monitoring the efficacy of therapy.

Performance Comment

PTN, also known as pleiotrophin, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.